Case Study: Leading Specialty Pharmaceutical Manufacturing Company achieves improved access to rare disease therapy with IntegriChain's unified data platform

Improving Access to Rare Disease Therapy through a Unified Data Platform

Leading Specialty Pharmaceutical Manufacturing Company faced the challenge of launching an orphan-disease therapy for a very small patient population that required a closed specialty pharmacy network, tight patient-journey monitoring, and predictable gross-to-net accounting. The company engaged IntegriChain beginning in 2019 for launch-readiness advisory work and to leverage the ICyte Platform and associated market-access services to manage pricing, contracting, and patient access complexities.

IntegriChain implemented a unified solution—combining the ICyte Platform with Gross-to-Net Advisory, Government Pricing and Rebate Managed Services, State Pricing Transparency support, and Patient Access solutions (Patient Data Aggregation, Refined Patient Data, and Specialty Pharmacy Analytics). The engagement produced audit-ready GTN forecasts and accruals, clearer longitudinal patient tracking and status reports, and improved operational insights that addressed common gaps (IntegriChain cites that ~80% of new patients often have ≥7‑day status-update gaps, with >40% showing ≥14‑day gaps). These outcomes enabled faster, more accurate commercial decisioning, compliance readiness, and better support for patient initiation and adherence.